Reference is made to the stock exchange notice from Hofseth BioCare ASA ("HBC" or the "Company") published on 3 July 2022 regarding the completion of a private placement raising gross proceeds of approximately NOK 141 million through issuance of new shares in the Company, and the primary insider notification on 3 July 2022 regarding, inter alia, a share lending agreement between the Company and Ødegård Prosjekt AS (a close associate of CFO Jon Olav Ødegård). All 958,810 shares lent out from Ødegård Prosjekt AS have now been redelivered to Ødegård Prosjekt AS.
Further information about the transaction is set out in the attached form.
For further information, please contact:
Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act section 5-12.
Attachment
